Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn
· theguardian.com · popularity 29/100 · 0 similar stories today · Medicine & Clinical Health (Health & Life Sciences)
Read the original at theguardian.com →
Summary
GLP-1 products such as Ozempic and Mounjaro spread but many in poorer countries struggle to get basic diabetes treatment The gold rush into GLP-1 weight-loss drugs risks diverting pharmaceutical firms’ attention away from diabetes treatments such as insulin, the head of the Access to Medicine Foundation has warned. GLP-1 blockbuster medications such as Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro have revolutionised obesity and diabetes treatment but there has been a greater focus by companies on weight loss, according to a report from the Netherlands-based non-profit group. Continue reading...
Found in: Guardian World. Rating basis: single outlet; outlet tier 5; 1 feeds; feed position 39.